{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/287730563"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "While BioCryst has an intriguing clinical pipeline for infectious diseases with blockbuster potential, my view is that the company is fairly valued given that its pipeline is mostly still in early stages of development, and the company already sports a market cap of $632 million." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "fool.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/50174669"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/287730563"] } } }
